<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-three children diagnosed with primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in a single institution over an 8 year period were evaluated with special emphasis on children who presented with extramedullary disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> was present at diagnosis in 12 (36%) of the 33 children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Three patients with juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>) and 2 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) presented with <z:hpo ids='HP_0002202'>pleural effusion</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001698'>Pericardial effusion</z:hpo> was present in 3 of these patients, two of whom also had <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000999'>Pyoderma</z:hpo> gangrenosum, <z:e sem="disease" ids="C0032453" disease_type="Disease or Syndrome" abbrv="">relapsing polychondritis</z:e> were the initial findings in another two cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002716'>Lymphadenopathy</z:hpo> (n=1), <z:hpo ids='HP_0000212'>gingival hypertrophy</z:hpo> (n=2), orbital granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (n=1) and spinal mass (n=1) were the presenting findings in 5 patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation </plain></SENT>
<SENT sid="6" pm="."><plain>Since high-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> (HDMP, 20-30 mg/kg/day) has been shown to induce differentiation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of myeloid leukemic cells in children with different morphological subtypes of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> in vivo and in vitro, 25 children with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were treated with combined HDMP and cytotoxic chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>Dramatic improvement of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> and decrease in blast cells both in the peripheral blood and bone marrow were obtained following administration of short-course HDMP treatment alone as observed in children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>HDMP, combined with low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> and <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> were used for the remission induction </plain></SENT>
<SENT sid="9" pm="."><plain>Remission was achieved in 8 (80%) of 10 children who presented with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> and in 9 (60%) of 15 children without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Long-term remission (&gt;6 years) was obtained in 4 (two with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> and two with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), three of whom presented with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> can be a presenting finding in childhood <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as observed in adults </plain></SENT>
<SENT sid="12" pm="."><plain>In addition, the beneficial effect of HDMP combined with more intensive chemotherapy should be explored as alternative therapy in children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> not suitable for bone marrow transplantation </plain></SENT>
</text></document>